Mankind Results Analysis

Q4FY25 – Operating Revenue Rs. 3,079 Cr. 27.1% Growth YoY, EBITDA Rs. 686 Cr. 16.4% Growth YoY, EBITDA Margin 22.3% 200 bps Negative Growth YoY, Profit after tax (PAT) Rs. 429 Cr. 10% Negative Growth YoY. FY25 – Operating Revenue Rs. 12,207 Cr. 19% Growth YoY, EBITDA Rs. 3,030 Cr. 19.8% Growth YoY, EBITDA Margin 24.8% 20 bps Growth YoY, Profit after tax (PAT) Rs. 2,007 Cr. 3.4% Growth YoY. Domestic Business Rs. 10,675 Cr. 13% Growth YoY, Export Business Rs. 1,532 Cr. 88% Growth YoY, Consumer Healthcare Business Rs. 809 Cr. 15% Growth YoY. Company acquired 100% stake of Bharat Serums and Vaccines (BSV) Ltd. In Oct-2024 for a cash consideration of Rs. 13,768 Crore.